Navigation Links
Imaging Diagnostic Systems Accepts Resignations of Outside Directors
Date:4/23/2008

Company Increases Focus on PMA Study

FORT LAUDERDALE, Fla., April 23 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS) announced that on April 16, 2008, the Company received and accepted the resignations of its three outside directors Jay Bendis, Patrick Gorman, and Sherman Lazrus. These resignations were tendered to comply with a request by outside funding sources as a condition to such funding. In connection with their resignations, these directors received full vesting on the options for 200,000 shares each, which the Company granted in early 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO )

Linda B. Grable, a co-founder of IDSI and its former Chairman of the Board and CEO, who retired in April 2004, agreed to come out of retirement and now serves as the Company's Chairman of the Board and interim CEO.

Allan Schwartz, Executive Vice President and CFO stated that, "I am gratified that Linda has come out of retirement to serve IDSI as Chairman of the Board and Interim CEO. Her passion and experience will be a driving force to enable the Company to achieve its financial goals and to complete the PMA filing process."

"As one of the original founders and a shareholder, I have a personal interest as well as a vested interest in IDSI's success," Grable commented. "I felt it was imperative for me to return to the company to help promote goodwill, bring value to the shareholders, and provide the avenue for the company to obtain the resources necessary to continue its operations and complete the PMA process. I am strongly committed to turning the original vision that I shared with my late husband Richard Grable, inventor of the CTLM system, into reality."

On April 18th, 2008 the company entered into a new "Sixth Private Equity Credit Agreement with Charlton Avenue LLC providing a maximum commitment of $15,000,000 for a period of three years from the effective date of registration statement.(for detailed information see April 16th 2008 Form 8-K)

While the Company believes that it will be able to secure the additional funding necessary on commercially reasonable terms and follow the PMA timetable, there can be no assurance that the Company will be able to do so.

About Imaging Diagnostic Systems, Inc.

Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM(R) system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM(R)) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.

The FDA has determined that the Company's clinical study is a non- significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The company is currently conducting clinical studies to collect the data necessary to support the FDA PMA application. The CTLM system is limited by United States Federal Law to investigational use only in the United States.

For more information, visit our website: http://www.imds.com

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Media Contact:

Deborah O'Brien

(954) 581-9800

obrien@imds.com


'/>"/>
SOURCE Imaging Diagnostic Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
2. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
3. Imaging Diagnostic Systems Generates Cash From Building Sale
4. Imaging quantum entanglement
5. Glycominds Joins Biomolecular Photonic (BMP) Consortium to Develop New Molecular Imaging Technique
6. Elbit Medical Imaging Ltd. Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore, India
7. Elbit Medical Imaging Ltd. Announces that Plaza Centers Has Entered into a Joint Venture Partnership to Develop Residential and Office Projects in Romania
8. Elbit Medical Imaging Ltd. Announces Results of Its Annual General Meeting
9. Imaging Diagnostic Systems Expands Key Patent Coverage
10. Imaging Diagnostic Systems Exhibits CT Laser Breast Imaging Results at Major Italian Multidisciplinary Breast Cancer Meeting
11. New Optical Breast Cancer Imaging Technology Garners Cover Story in National Radiology Magazine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... February 27, 2017 Four US ... evaluation today, and they are: Anthera Pharmaceuticals Inc. (NASDAQ: ... California Inc. (NASDAQ: PACB), and Conatus Pharmaceuticals Inc. (NASDAQ: ... ETF Trends, market observers are growing more bullish on ... enact reforms to free cash held overseas for tax ...
(Date:2/26/2017)... ... ... Rob Lowe is a well recognized television personality, so it seems natural he would ... important to the American public and important to society at large. An upcoming episode ... the world for a few years. , The climate and how we relate to ...
(Date:2/24/2017)... KNOXVILLE, Tenn. , Feb. 24, 2017 /PRNewswire/ ... ) ("Provectus" or the "Company"), a clinical-stage oncology ... information regarding the deadline to participate in its ... million units, consisting of shares of common stock ... stockholders and holders of listed warrants. ...
(Date:2/24/2017)... Staten Island, NY (PRWEB) , ... February 24, 2017 , ... ... exponential rate. Founded in late 2014, FireflySci had the goal of bringing their ... 2017, that goal continues to shape the path that FireflySci is going on as ...
Breaking Biology Technology:
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
(Date:2/6/2017)... According to Acuity Market Intelligence, ongoing ... to continue to embrace biometric and digital identification ... Border Control (ABC) eGates and 1436 Automated Passport ... 163 ports of entry across the globe. Deployments ... combined CAGR of 37%. APC Kiosks reached 75% ...
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
Breaking Biology News(10 mins):